RxDoctor Payments Data

William Bevers, MD

Family Medicine · Oklahoma City, OKNPI 1922070317

Payments from drug & device makers

$8,660in general payments, 2019–2025

Across 543 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$930
  • Pfizer$885
  • AbbVie$859
  • Lilly USA, LLC$533
  • Astellas Pharma US Inc$421
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,47598%
  • Education$1852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,660 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$183,657
Medicare patients
498
Services billed
8,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide198$252,634
JardianceEmpagliflozin70$95,112
FarxigaDapagliflozin Propanediol85$78,296
JanuviaSitagliptin Phosphate75$75,245
TrulicityDulaglutide28$56,708
EliquisApixaban40$47,411
XareltoRivaroxaban42$29,525
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$24,074
MyrbetriqMirabegron25$21,948
Tresiba Flextouch U-200Insulin Degludec21$13,303
JanumetSitagliptin Phos/Metformin Hcl13$12,040
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$9,563
Breo ElliptaFluticasone/Vilanterol15$9,086
TrulancePlecanatide12$6,739
BelsomraSuvorexant13$5,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,099$252,634198 claims
Boehringer IngelheimJardiance$237$95,11270 claims
MerckJanuvia, Janumet, Belsomra$247$93,168101 claims
AstraZenecaFarxiga$930$78,29685 claims
Lilly USA, LLCTrulicity$533$56,70828 claims
PfizerEliquis$885$47,41140 claims
GSKTrelegy Ellipta, Breo Ellipta$406$33,16149 claims
Johnson & JohnsonXarelto$22$29,52542 claims
Astellas Pharma US IncMyrbetriq$421$21,94825 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$16$6,73912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →